Open Access
Open access
Cell Reports, volume 39, issue 7, pages 110812

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Stefanie Žentelis 1
LINGSHU WANG 2
Denisa Foster 3
Peter Vaillancourt 3
Matthew Wiggin 1
Erica Lovett 1
Robin van der Lee 1
Jörg Hendle 3
Anna Pustilnik 3
J.Michael Sauder 3
Lucas Kraft 1
Yuri Hwang 1
Robert W Siegel 4
Jinbiao Chen 4
Beverly A. Heinz 4
Richard E Higgs 4
Nicole L. Kallewaard 4
Kevin Jepson 1
Rodrigo Goya 1
Maia A Smith 1
David W Collins 1
Davide Pellacani 1
Ping Xiang 1
Valentine De Puyraimond 1
Marketa Ricicova 1
Lindsay DeVorkin 1
Caitlin Pritchard 1
Aoise Oneill 1
Kush Dalal 1
Pankaj Panwar 1
Harveer Dhupar 1
Fabian Garces 1
Courtney A. Cohen 5
John M. Dye 5
Kathleen E. Huie 5
Catherine V. Badger 5
D. Kobasa 6, 7
Jonathan Audet 6, 7
Joshua J Freitas 3
Saleema Hassanali 3
Ina Hughes 3
Luis Munoz 3
Holly C Palma 3
Bharathi Ramamurthy 3
Robert W. Cross 7, 8, 9
Thomas W. Geisbert 7, 8, 9
Vineet Menachery 8, 9
Kumari Lokugamage 8, 9
Viktoriya Borisevich 8, 9
Iliana Lanz 1
Lisa Anderson 1
Payal Sipahimalani 1
Kizzmekia S Corbett 2
Eun Sung Yang 2
ZHANG Yi 2
Wei Shi 2
Tongqing ZHOU 2
Misook Choe 2
John Misasi 2
Peter D. Kwong 2
Nancy J. Sullivan 2
B. Graham 2
Tara L. Fernandez 1
Carl L. Hansen 1
John Mascola 2
Bryan C. Barnhart 1
1
 
AbCellera Biologics Inc., Vancouver, BC V5Y 0A1, Canada
3
 
Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA
4
 
Eli Lilly and Company, Indianapolis, IN 46285, USA
5
 
U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA
6
 
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3L5, Canada
7
 
University of Manitoba, Winnipeg, MB R3T 2N2, Canada
8
 
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA
9
 
Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA
Publication typeJournal Article
Publication date2022-05-01
Journal: Cell Reports
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor8.8
ISSN22111247
General Biochemistry, Genetics and Molecular Biology
Abstract

Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.

Top-30

Citations by journals

2
4
6
8
10
12
Cell Reports
11 publications, 3.81%
iScience
9 publications, 3.11%
Viruses
7 publications, 2.42%
Nature Communications
6 publications, 2.08%
Cell Host and Microbe
6 publications, 2.08%
International Journal of Molecular Sciences
5 publications, 1.73%
Nature
5 publications, 1.73%
Frontiers in Immunology
4 publications, 1.38%
PLoS Pathogens
4 publications, 1.38%
Cell
4 publications, 1.38%
Cell Reports Medicine
4 publications, 1.38%
Emerging Microbes and Infections
4 publications, 1.38%
Science immunology
3 publications, 1.04%
Vaccines
3 publications, 1.04%
Antibodies
3 publications, 1.04%
Signal Transduction and Targeted Therapy
3 publications, 1.04%
Scientific Reports
3 publications, 1.04%
Science Translational Medicine
3 publications, 1.04%
The Lancet Infectious Diseases
3 publications, 1.04%
Journal of Infectious Diseases
3 publications, 1.04%
Journal of Virology
3 publications, 1.04%
Science
3 publications, 1.04%
Proceedings of the National Academy of Sciences of the United States of America
3 publications, 1.04%
Antibody Therapeutics
3 publications, 1.04%
Virology Journal
2 publications, 0.69%
Nature Immunology
2 publications, 0.69%
Pathogens
2 publications, 0.69%
Pharmaceuticals
2 publications, 0.69%
Life
2 publications, 0.69%
2
4
6
8
10
12

Citations by publishers

10
20
30
40
50
60
70
80
Elsevier
75 publications, 25.95%
Cold Spring Harbor Laboratory
49 publications, 16.96%
Springer Nature
44 publications, 15.22%
Multidisciplinary Digital Publishing Institute (MDPI)
32 publications, 11.07%
American Association for the Advancement of Science (AAAS)
11 publications, 3.81%
Frontiers Media S.A.
10 publications, 3.46%
Oxford University Press
10 publications, 3.46%
Taylor & Francis
7 publications, 2.42%
Public Library of Science (PLoS)
6 publications, 2.08%
Wiley
6 publications, 2.08%
American Society for Microbiology
6 publications, 2.08%
American Chemical Society (ACS)
4 publications, 1.38%
Proceedings of the National Academy of Sciences (PNAS)
3 publications, 1.04%
Bentham Science
2 publications, 0.69%
Wolters Kluwer Health
2 publications, 0.69%
American Society of Hematology
2 publications, 0.69%
Mary Ann Liebert
1 publication, 0.35%
American College of Allergy, Asthma, & Immunology
1 publication, 0.35%
KeAi Communications Co.
1 publication, 0.35%
Thieme
1 publication, 0.35%
Rockefeller University Press
1 publication, 0.35%
Royal Society of Chemistry (RSC)
1 publication, 0.35%
PagePress
1 publication, 0.35%
IGI Global
1 publication, 0.35%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.35%
10
20
30
40
50
60
70
80
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Westendorf K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants // Cell Reports. 2022. Vol. 39. No. 7. p. 110812.
GOST all authors (up to 50) Copy
Westendorf K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants // Cell Reports. 2022. Vol. 39. No. 7. p. 110812.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.celrep.2022.110812
UR - https://doi.org/10.1016/j.celrep.2022.110812
TI - LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
T2 - Cell Reports
AU - Westendorf, Kathryn
AU - Žentelis, Stefanie
AU - WANG, LINGSHU
AU - Foster, Denisa
AU - Vaillancourt, Peter
AU - Wiggin, Matthew
AU - Lovett, Erica
AU - der Lee, Robin van
AU - Hendle, Jörg
AU - Pustilnik, Anna
AU - Sauder, J.Michael
AU - Kraft, Lucas
AU - Hwang, Yuri
AU - Siegel, Robert W
AU - Chen, Jinbiao
AU - Heinz, Beverly A.
AU - Higgs, Richard E
AU - Kallewaard, Nicole L.
AU - Jepson, Kevin
AU - Goya, Rodrigo
AU - Smith, Maia A
AU - Collins, David W
AU - Pellacani, Davide
AU - Xiang, Ping
AU - De Puyraimond, Valentine
AU - Ricicova, Marketa
AU - DeVorkin, Lindsay
AU - Pritchard, Caitlin
AU - Oneill, Aoise
AU - Dalal, Kush
AU - Panwar, Pankaj
AU - Dhupar, Harveer
AU - Garces, Fabian
AU - Cohen, Courtney A.
AU - Dye, John M.
AU - Huie, Kathleen E.
AU - Badger, Catherine V.
AU - Kobasa, D.
AU - Audet, Jonathan
AU - Freitas, Joshua J
AU - Hassanali, Saleema
AU - Hughes, Ina
AU - Munoz, Luis
AU - Palma, Holly C
AU - Ramamurthy, Bharathi
AU - Cross, Robert W.
AU - Geisbert, Thomas W.
AU - Menachery, Vineet
AU - Lokugamage, Kumari
AU - Borisevich, Viktoriya
AU - Lanz, Iliana
AU - Anderson, Lisa
AU - Sipahimalani, Payal
AU - Corbett, Kizzmekia S
AU - Yang, Eun Sung
AU - Yi, ZHANG
AU - Shi, Wei
AU - ZHOU, Tongqing
AU - Choe, Misook
AU - Misasi, John
AU - Kwong, Peter D.
AU - Sullivan, Nancy J.
AU - Graham, B.
AU - Fernandez, Tara L.
AU - Hansen, Carl L.
AU - Falconer, Ester
AU - Mascola, John
AU - Jones, Bryan E
AU - Barnhart, Bryan C.
PY - 2022
DA - 2022/05/01 00:00:00
PB - Elsevier
SP - 110812
IS - 7
VL - 39
PMID - 35568025
SN - 2211-1247
ER -
BibTex |
Cite this
BibTex Copy
@article{2022_Westendorf,
author = {Kathryn Westendorf and Stefanie Žentelis and LINGSHU WANG and Denisa Foster and Peter Vaillancourt and Matthew Wiggin and Erica Lovett and Robin van der Lee and Jörg Hendle and Anna Pustilnik and J.Michael Sauder and Lucas Kraft and Yuri Hwang and Robert W Siegel and Jinbiao Chen and Beverly A. Heinz and Richard E Higgs and Nicole L. Kallewaard and Kevin Jepson and Rodrigo Goya and Maia A Smith and David W Collins and Davide Pellacani and Ping Xiang and Valentine De Puyraimond and Marketa Ricicova and Lindsay DeVorkin and Caitlin Pritchard and Aoise Oneill and Kush Dalal and Pankaj Panwar and Harveer Dhupar and Fabian Garces and Courtney A. Cohen and John M. Dye and Kathleen E. Huie and Catherine V. Badger and D. Kobasa and Jonathan Audet and Joshua J Freitas and Saleema Hassanali and Ina Hughes and Luis Munoz and Holly C Palma and Bharathi Ramamurthy and Robert W. Cross and Thomas W. Geisbert and Vineet Menachery and Kumari Lokugamage and Viktoriya Borisevich and Iliana Lanz and Lisa Anderson and Payal Sipahimalani and Kizzmekia S Corbett and Eun Sung Yang and ZHANG Yi and Wei Shi and Tongqing ZHOU and Misook Choe and John Misasi and Peter D. Kwong and Nancy J. Sullivan and B. Graham and Tara L. Fernandez and Carl L. Hansen and Ester Falconer and John Mascola and Bryan E Jones and Bryan C. Barnhart},
title = {LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants},
journal = {Cell Reports},
year = {2022},
volume = {39},
publisher = {Elsevier},
month = {may},
url = {https://doi.org/10.1016/j.celrep.2022.110812},
number = {7},
pages = {110812},
doi = {10.1016/j.celrep.2022.110812}
}
MLA
Cite this
MLA Copy
Westendorf, Kathryn, et al. “LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.” Cell Reports, vol. 39, no. 7, May. 2022, p. 110812. https://doi.org/10.1016/j.celrep.2022.110812.
Found error?